- Home
- Companies
- canada quebec
- clinical phase
Show results for
Refine by
Industries served
- Medical / Health Care
- Chemical & Pharmaceuticals
- Monitoring and Testing
- Health and Safety
- Manufacturing, Other
- Automobile & Ground Transport
- Defense
- Electronics and Computers
- Aerospace & Air Transport
- Waste and Recycling
- Oil, Gas & Refineries
- Environmental
- Air and Climate
- University / Academia / Research
- Government
- Food and Beverage
- Energy
Clinical Phase Suppliers Serving Quebec
118 companies found
based inMumbai, INDIA
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of ...
The NDDD team has developed a pipeline of highly differentiated and innovative new chemical entities in focused therapeutic areas of Oncology, Immunology and Metabolic ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
When you perform intraperitoneal injection of hapten or highly homologous antigens in mouse species, most of the time your project is going to fail. Due to poor immunogenic properties and low molecular weight, your antigen is going to be eliminated ...
based inNew York, NEW YORK (USA)
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic ...
Medidata AI Synthetic Control Arm (SCA®) offers the only external control arm created with cross-industry historical clinical trial data from 25,000+ clinical trials and 7 million patients. SCA can enable scientific research, cut costs and ...
based inLebanon, NEW HAMPSHIRE (USA)
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream. ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
We are building an active pipeline of products for human health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases. Vaccine Development: The C1 platform is ready for full ...
based inKaiseraugst, SWITZERLAND
Solvias is a world leader in contract research, development and manufacturing (CRO/CDMO). The industries we serve include pharmaceuticals, biotech, medical devices and cosmetics. We provide integrated analytical services and solutions to the ...
We provide rapid and comprehensive support for your early-phase drug development process, enabling you to establish 'critical mass' – in terms of personnel and know-how – in the chemical and analytical development of complex ...
based inVienna, AUSTRIA
A spin-off from the University of Veterinary Medicine Vienna, ViruSure was founded in 2005 by Dr. Andy Bailey to offer a range of biosafety testing services to biopharmaceutical product manufacturers. Since 2008, ViruSure’s in vitro and molecular ...
Recombinant proteins are proteins expressed in cell lines which have been genetically modified by DNA recombinant technology. These therapeutics include recombinant blood clotting factors, hormones, enzymes, interferons, growth factors and other ...
based inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
More effective pain relief may also allow patients to avoid the problems of opioid therapies often used for the treatment of post-surgical pain.In a Phase I/II clinical trial in patients following hernia repair ...
based inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of ...
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
Background to the NTCD-M3 Clostridioides difficile Programme. NTCD-M3 was developed by GI infection physician, Professor Dale Gerding, who is a world-leading specialist in C. difficile, with more than 400 peer-reviewed journal publications, book ...
based inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
IL-15,Interleukin-15,IL15,Interleukin ...
based inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic ...
based inNorth Brunswick, NEW JERSEY (USA)
Ascendia Pharmaceutical Solutions specializes in comprehensive drug development services, providing tailored formulation and manufacturing solutions from pre-formulation stages to commercialization. With a focus on overcoming pharmaceutical ...
based inMalmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
Oncoral is a daily irinotecan tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase ...
based inOxford, UNITED KINGDOM
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help ...
Pharmacokinetic (PK) & Pharmacodynamic (PD) modelling is often an integral component in the drug development process. PK involves studying the movement of a certain drug dose in the body. PD involves studying how a certain drug dose affects the ...
based inTübingen, GERMANY
Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company ...
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral diseases: COVID-19 and influenza, two ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Constellation Pharmaceuticals, a MorphoSys company, is using a starting dose of 125 mg in MANIFEST, our global, multicenter, open-label Phase 2 study of pelabresib in patients with Myelofibrosis (MF). Preclinical studies and ...